Roche Czech Republic

Roche CR's net profit rose 394% to CZK 252 mil in 2016

By Helgi Analytics - November 05, 2019

Roche Czech Republic made a net profit of CZK 252 mil in 2016, up 394% when compared to the last year. Total sales reached CZK 4,962...

Roche CR's employees rose 5.91% to 251 in 2016

By Helgi Analytics - November 05, 2019

Roche Czech Republic employed 251 persons in 2016, up 5.91% when compared to the previous year. Historically, the firm's workforce h...

Roche CR's Net Margin rose 442% yoy to 5.08% in 2016

By Helgi Analytics - November 05, 2019

Roche Czech Republic made a net profit of CZK 252 mil under revenues of CZK 4,962 mil in 2016, up 394% and -8.88%, respectively, ...

Profit Statement 2014 2015 2016
Sales CZK mil 4,364 5,445 4,962
Gross Profit CZK mil 763 1,489 784
EBITDA CZK mil 265 209 475
EBIT CZK mil 134 81.5 352
Financing Cost CZK mil 1.12 0.819 1.81
Pre-Tax Profit CZK mil 133 80.6 350
Net Profit CZK mil 94.9 51.0 252
Balance Sheet 2014 2015 2016
Total Assets CZK mil 2,317 2,548 2,647
Non-Current Assets CZK mil 334 319 292
Current Assets CZK mil 1,962 2,228 2,276
Working Capital CZK mil 1,532 1,659 1,667
Shareholders' Equity CZK mil 1,134 1,185 1,436
Liabilities CZK mil 1,183 1,364 1,210
Total Debt CZK mil 541 660 203
Net Debt CZK mil 541 660 203
Ratios 2014 2015 2016
ROE % 8.00 4.40 19.2
ROCE % 5.39 2.65 12.8
Gross Margin % 17.5 27.3 15.8
EBITDA Margin % 6.07 3.84 9.57
EBIT Margin % 3.07 1.50 7.10
Net Margin % 2.17 0.936 5.08
Net Debt/EBITDA 2.04 3.15 0.428
Net Debt/Equity % 47.7 55.7 14.2
Cost of Financing % 0.272 0.136 0.420
Cash Flow 2014 2015 2016
Total Cash From Operations CZK mil 66.8 -4.71 621
Total Cash From Investing CZK mil -125 -114 -94.9
Total Cash From Financing CZK mil 56.2 118 -458
Net Change In Cash CZK mil -2.04 -0.259 68.3
Cash Conversion Cycle days 136 127 129
Cash Earnings CZK mil 226 179 374
Free Cash Flow CZK mil -58.3 -118 526

Get all company financials in excel:

Download Sample   $19.99

summary Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
income statement                            
Sales CZK mil               5,073 5,011 4,869 4,934 4,364    
Gross Profit CZK mil               680 620 634 770 763    
EBIT CZK mil               138 83.1 69.0 183 134    
Net Profit CZK mil               101 50.5 38.7 135 94.9    
ROE %               10.5 4.85 3.57 11.5 8.00    
EBIT Margin %               2.72 1.66 1.42 3.71 3.07    
Net Margin %               1.99 1.01 0.794 2.73 2.17    
Employees               226 220 216 216 202    
balance sheet                            
Total Assets CZK mil               2,473 2,238 2,344 2,245 2,317    
Non-Current Assets CZK mil               386 329 354 338 334    
Current Assets CZK mil               2,085 1,971 1,988 1,905 1,962    
Shareholders' Equity CZK mil               1,015 1,065 1,104 1,239 1,134    
Liabilities CZK mil               1,458 1,173 1,240 1,006 1,183    
Non-Current Liabilities CZK mil               0.949 1.46 0 0 0    
Current Liabilities CZK mil               1,451 1,163 1,231 978 1,168    
Net Debt/EBITDA               1.67 -0.002 0.737 0.867 2.04    
Net Debt/Equity %               41.6 -0.035 13.7 23.0 47.7    
Cost of Financing % ...             1.19 0.316 -2.24 0.681 0.272    
cash flow                            
Total Cash From Operations CZK mil               -232 65.2 159 127 66.8    
Total Cash From Investing CZK mil               -158 -65.5 -159 -127 -125    
Total Cash From Financing CZK mil               390 0 0 0 56.2    
Net Change In Cash CZK mil               0.195 -0.286 -0.134 0.104 -2.04    
income statement Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
income statement                            
Sales CZK mil               5,073 5,011 4,869 4,934 4,364    
Cost of Goods & Services CZK mil               4,393 4,392 4,235 4,164 3,601    
Gross Profit CZK mil               680 620 634 770 763    
Staff Cost CZK mil               338 329 345 373 373    
Other Cost CZK mil               88.8 82.6 85.0 68.6 125    
EBITDA CZK mil               254 208 204 328 265    
Depreciation CZK mil               116 125 135 145 131    
EBIT CZK mil               138 83.1 69.0 183 134    
Financing Cost CZK mil               2.72 0.669 -1.69 1.48 1.12    
Extraordinary Cost CZK mil               0 0 0 0 0    
Pre-Tax Profit CZK mil               135 82.4 70.7 182 133    
Tax CZK mil               34.2 31.9 32.0 46.9 38.1    
Minorities CZK mil               0 0 0 0 0    
Net Profit CZK mil               101 50.5 38.7 135 94.9    
growth rates                            
Total Revenue Growth % ...             4.27 -1.23 -2.83 1.33 -11.5    
Operating Cost Growth % ...             -14.5 -3.47 4.38 2.78 12.6    
EBITDA Growth % ...             8.45 -18.2 -1.49 60.6 -19.3    
EBIT Growth % ...             8.91 -39.8 -16.9 165 -26.8    
Pre-Tax Profit Growth % ...             8.03 -39.1 -14.2 157 -26.8    
Net Profit Growth % ...             15.7 -50.1 -23.3 248 -29.6    
ratios                            
ROE %               10.5 4.85 3.57 11.5 8.00    
ROCE % ...             8.06 4.01 3.25 8.93 5.39    
Gross Margin %               13.4 12.4 13.0 15.6 17.5    
EBITDA Margin %               5.00 4.14 4.20 6.66 6.07    
EBIT Margin %               2.72 1.66 1.42 3.71 3.07    
Net Margin %               1.99 1.01 0.794 2.73 2.17    
Cost of Financing % ...             1.19 0.316 -2.24 0.681 0.272    
Net Debt/EBITDA               1.67 -0.002 0.737 0.867 2.04    
balance sheet Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
balance sheet                            
Non-Current Assets CZK mil               386 329 354 338 334    
Property, Plant & Equipment CZK mil               386 329 354 338 334    
Intangible Assets CZK mil               0 0 0 0 0    
Current Assets CZK mil               2,085 1,971 1,988 1,905 1,962    
Inventories CZK mil               1,409 767 872 775 828    
Receivables CZK mil               635 983 1,087 1,108 1,101    
Cash & Cash Equivalents CZK mil               0.662 0.376 0.242 0.346 0.305    
Total Assets CZK mil               2,473 2,238 2,344 2,245 2,317    
Shareholders' Equity CZK mil               1,015 1,065 1,104 1,239 1,134    
Of Which Minority Interest CZK mil               0 0 0 0 0    
Liabilities CZK mil               1,458 1,173 1,240 1,006 1,183    
Non-Current Liabilities CZK mil               0.949 1.46 0 0 0    
Long-Term Debt CZK mil               0 0 0 0 0    
Deferred Tax Liabilities CZK mil               0.949 1.46 0 0 0    
Current Liabilities CZK mil               1,451 1,163 1,231 978 1,168    
Short-Term Debt CZK mil               423 0 151 285 541    
Trade Payables CZK mil               936 1,056 953 562 397    
Provisions CZK mil               6.38 7.65 9.24 27.6 15.0    
Equity And Liabilities CZK mil               2,473 2,238 2,344 2,245 2,317    
growth rates                            
Total Asset Growth % ...             23.2 -9.52 4.74 -4.23 3.23    
Shareholders' Equity Growth % ...             11.1 4.97 3.63 12.2 -8.48    
Net Debt Growth % ...             1,193 -100 -40,192 88.9 90.0    
Total Debt Growth % ...           ... 1,177 -100 ... 88.9 89.9    
ratios                            
Total Debt CZK mil               423 0 151 285 541    
Net Debt CZK mil               422 -0.376 151 285 541    
Working Capital CZK mil               1,108 694 1,007 1,321 1,532    
Capital Employed CZK mil               1,495 1,023 1,361 1,659 1,865    
Net Debt/Equity %               41.6 -0.035 13.7 23.0 47.7    
Cost of Financing % ...             1.19 0.316 -2.24 0.681 0.272    
cash flow Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
cash flow                            
Net Profit CZK mil               101 50.5 38.7 135 94.9    
Depreciation CZK mil               116 125 135 145 131    
Non-Cash Items CZK mil ...             -14.5 -524 297 161 51.9    
Change in Working Capital CZK mil ...             -434 414 -312 -314 -211    
Total Cash From Operations CZK mil               -232 65.2 159 127 66.8    
Capital Expenditures CZK mil               -163 -77.6 -165 -143 -132    
Other Investments CZK mil               5.21 12.1 5.53 16.2 6.80    
Total Cash From Investing CZK mil               -158 -65.5 -159 -127 -125    
Issuance Of Debt CZK mil ...             390 -423 151 134 256    
Total Cash From Financing CZK mil               390 0 0 0 56.2    
Net Change In Cash CZK mil               0.195 -0.286 -0.134 0.104 -2.04    
ratios                            
Days Sales Outstanding days               45.7 71.6 81.5 81.9 92.1    
Days Sales Of Inventory days               117 63.7 75.2 67.9 83.9    
Days Payable Outstanding days               77.7 87.8 82.1 49.3 40.2    
Cash Conversion Cycle days               85.0 47.6 74.5 101 136    
Cash Earnings CZK mil               217 175 174 280 226    
Free Cash Flow CZK mil               -390 -0.286 -0.134 0.104 -58.3    
other data Unit 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
other data                            
ROA %               4.52 2.14 1.69 5.88 4.16    
Gross Margin %               13.4 12.4 13.0 15.6 17.5    
Employees               226 220 216 216 202    
Cost Per Employee USD per month               6,520 7,054 6,805 7,362 7,192    
Cost Per Employee (Local Currency) CZK per month               124,598 124,765 133,116 144,043 153,708    
Staff Cost (As % Of Total Cost) %               6.85 6.68 7.19 7.86 8.81    
Effective Tax Rate %               25.2 38.8 45.3 25.8 28.6    
Domestic Sales CZK mil ... ... ... ... ... ... ... ... ... ... ... ...    
Capital Expenditures (As % of Sales) %               3.22 1.55 3.38 2.90 3.02    
Revenues From Abroad CZK mil ... ... ... ... ... ... ... ... ... ... ... 265    
Revenues From Abroad (As % Of Total) % ... ... ... ... ... ... ... ... ... ... ... 6.08    
Sales of Pharmaceutical Products & Medical Devices CZK mil               4,729 4,686 4,568 4,606 4,086    
Sales from Reinvoicing & Services CZK mil               344 326 301 328 278    
Sales from Pharmaceuticals Division CZK mil ...             3,721 3,630 3,533 3,806 3,192 ... ...
Sales from Diagnostics & Diabetes Care Division CZK mil ...             1,009 1,082 1,035 1,128 1,172 ... ...

Get all company financials in excel:

Download Sample   $19.99

Roche CR's ROCE rose 382% to 12.8% in 2016

By Helgi Analytics - November 05, 2019

Roche Czech Republic made a net profit of CZK 252 mil in 2016, up 394% when compared to the previous year. Historically, company's net profit reached an all time high of CZK 252 mil in 2016 and an all time low of CZK 16.8 mil in 2007. This implies return on equity...

Roche CR's Total Cash From Operations rose 13,281% to CZK 621 mil in 2016

By Helgi Analytics - November 05, 2019

Roche Czech Republic's operating cash flow reached CZK 621 mil in 2016, up 13,281% when compared to the previous year. Historically, the firm’s operating cash flow reached an all time high of CZK 730 mil in 2008 and an all time low of CZK -420 mil in 2005. R...

Roche CR's Net Debt/EBITDA fell 86.4% to 0.428 in 2016

By Helgi Analytics - November 05, 2019

Roche Czech Republic's net debt reached CZK 203 mil and accounted for 14.2% of equity at the end of 2016. The ratio is down 74.6% when compared to the previous year. Historically, the firm’s net debt to equity reached an all time high of 113% in 2004 and an all t...

Roche CR's Capital Expenditures fell 2.81% to CZK 114 mil in 2016

By Helgi Analytics - November 05, 2019

Roche Czech Republic invested total of CZK 114 mil in 2016, down 2.81% when compared to the previous year. Historically, company's investments reached an all time high of CZK 165 mil in 2012 and an all time low of CZK 77.6 mil in 2011. When compared to ...

Roche CR's Cash & Cash Equivalents fell 71.7% to CZK 0.013 mil in 2016

By Helgi Analytics - November 05, 2019

Roche Czech Republic's total assets reached CZK 2,647 mil at the end of 2016, up 8.14% when compared to the previous year. Current assets amounted to CZK 2,276 mil, or 86.0% of total assets while cash reached CZK 0.013 mil at the end of 2016. On the other hand, total debt ...

More News

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was the fifth-largest pharma company worldwide. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares.

Roche Czech Republic Logo